title: Cisplatin plus docetaxel combination in the first-line treatment of metastatic non-small cell lung cancer.
abstract: OBJECTIVE
  To evaluate activity and toxicity of cisplatin plus docetaxel combination in the first-line treatment of chemotherapy-naive patients with metastatic non-small cell lung cancer.
  
  
  METHODS
  Between October 2004 and July 2008, 186 patients with metastatic non-small cell lung cancer treated with first-line cisplatin plus docetaxel were retrospectively evaluated in 7 centers. The chemotherapy schedule consisted of cisplatin, 75 mg/m(2) iv infusion, and docetaxel, 75 mg/m(2) iv infusion on day 1, every 3 weeks.
  
  
  RESULTS
  Median age was 56 years (range, 28-75). Eighteen patients (9.7%) were females and 168 (90.3%) were males, with a median ECOG performance status of 1 (range, 0-2). A total of 833 cycles of chemotherapy was administered (median, 4 cycles; range, 1-6). Two patients (1.1%) achieved clinical complete response, 77 patients (41.4%) partial response, and 66 patients (35.5%) stable disease. Median time to disease progression was 6 months (95% CI, 5.54-6.46). Median overall survival was 14.6 months (95% CI, 11.47-17.73). One- and 2-year overall survival was 55.2% and 19.7%, respectively. The most common grade 3-4 hematological toxicities were neutropenia (n = 32, 17.2%) and anemia (n = 4, 2.2%).
  
  
  CONCLUSIONS
  The cisplatin plus docetaxel combination was effective and safe in the first-line treatment of patients with metastatic non-small cell lung cancer.
authors.affiliation: Gazi University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey.
authors.forename: Ali Osman
authors.initials: AO
authors.lastname: Kaya
authors.forename: Suleyman
authors.initials: S
authors.lastname: Buyukberber
authors.forename: Faysal
authors.initials: F
authors.lastname: Dane
authors.forename: Abdurrahman
authors.initials: A
authors.lastname: Isikdogan
authors.forename: Basak Oven
authors.initials: BO
authors.lastname: Ustaalioglu
authors.forename: Ugur
authors.initials: U
authors.lastname: Coskun
authors.forename: Perran Fulden
authors.initials: PF
authors.lastname: Yumuk
authors.forename: Gamze Gokoz
authors.initials: GG
authors.lastname: Dogu
authors.forename: Nuriye Yildirim
authors.initials: NY
authors.lastname: Ozdemir
authors.forename: Alper
authors.initials: A
authors.lastname: Sevinc
authors.forename: Mahmut
authors.initials: M
authors.lastname: Gumus
authors.forename: Metin
authors.initials: M
authors.lastname: Ozkan
authors.forename: Ramazan
authors.initials: R
authors.lastname: Yildiz
authors.forename: Banu
authors.initials: B
authors.lastname: Ozturk
authors.forename: Emel
authors.initials: E
authors.lastname: Yaman
authors.forename: Mustafa
authors.initials: M
authors.lastname: Benekli
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012189:Retrospective Studies; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D014421:Turkey
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin